These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8131699)

  • 41. An endoscopic evaluation of the effects of etodolac and diclofenac on the gastric and duodenal mucosa.
    van Eeden A; Schotborgh RH; Tytgat GN
    Clin Ther; 1990; 12(6):496-502. PubMed ID: 2149673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nabumetone: a "nonacidic" nonsteroidal antiinflammatory drug.
    Dahl SL
    Ann Pharmacother; 1993 Apr; 27(4):456-63. PubMed ID: 8477124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation.
    Inoue K; Motonaga A; Dainaka J; Nishimura T; Hashii H; Yamate K; Ueda F; Kimura K
    Prostaglandins Leukot Essent Fatty Acids; 1994 Dec; 51(6):457-62. PubMed ID: 7708812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology.
    Mangan FR; Flack JD; Jackson D
    Am J Med; 1987 Oct; 83(4B):6-10. PubMed ID: 3688000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro investigation of the effects of cyclooxygenase-2 inhibitors on contractile activity of the equine dorsal and ventral colon.
    Van Hoogmoed LM; Snyder JR; Harmon FA
    Am J Vet Res; 2002 Nov; 63(11):1496-500. PubMed ID: 12428657
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of selected newer nonsteroidal anti-inflammatory drugs.
    Cummings DM; Amadio P
    Am Fam Physician; 1994 Apr; 49(5):1197-202. PubMed ID: 8154406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological properties of the new non-steroidal anti-inflammatory agent etodolac.
    Inoue K; Fujisawa H; Sasaki Y; Nishimura T; Nishimura I; Inoue Y; Yokota M; Masuda T; Ueda F; Shibata Y
    Arzneimittelforschung; 1991 Mar; 41(3):228-35. PubMed ID: 1651085
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastric mucosal adaptation to etodolac and naproxen.
    Lipscomb GR; Wallis N; Armstrong G; Goodman MJ; Rees WD
    Aliment Pharmacol Ther; 1995 Aug; 9(4):379-85. PubMed ID: 8527613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of nabumetone and dipyrone on experimentally induced gastric ulcers in rats.
    Yıldırım E; Sağıroğlu O; Kılıç FS; Erol K
    Inflammation; 2013 Apr; 36(2):476-81. PubMed ID: 23129452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastrointestinal toxicity of newer NSAIDs.
    Lanza FL
    Am J Gastroenterol; 1993 Sep; 88(9):1318-23. PubMed ID: 8362824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of chronic treatment with indomethacin at clinically relevant doses on intestinal tissue 6-keto prostaglandin F1 alpha and leukotriene B4 level in relation to gastroenteropathy.
    Uçar A; Sak SD; Melli M
    Inflammation; 1998 Jun; 22(3):243-52. PubMed ID: 9604712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of nabumetone treatment on vascular responses of the thoracic aorta in rat experimental arthritis.
    Ulker S; Onal A; Hatip FB; Sürücü A; Alkanat M; Koşay S; Evinç A
    Pharmacology; 2000 Apr; 60(3):136-42. PubMed ID: 10754450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gastric mucosal resistance and prostanoid levels after cimetidine treatment in rats.
    Arakawa T; Satoh H; Fukuda T; Sakuma H; Nakamura H; Kobayashi K
    Digestion; 1988; 41(1):1-8. PubMed ID: 3203823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.
    Bianchi Porro G; Montrone F; Petrillo M; Caruso I; Imbesi V
    Am J Gastroenterol; 1995 Sep; 90(9):1485-8. PubMed ID: 7661175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The enantiomers of etodolac, a racemic anti-inflammatory agent, play different roles in efficacy and gastrointestinal safety.
    Inoue N; Nogawa M; Ito S; Tajima K; Kume S; Kyoi T
    Biol Pharm Bull; 2011; 34(5):655-9. PubMed ID: 21532152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of ecabet sodium (TA-2711), a new antiulcer agent, on gastrointestinal mucosal prostanoid production and morphology in rats.
    Kinoshita M; Iwasaki H; Yasoshima A; Tamaki H
    Biol Pharm Bull; 1993 Dec; 16(12):1220-5. PubMed ID: 8130770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of nabumetone on prostanoid biosynthesis in humans.
    Cipollone F; Ganci A; Panara MR; Greco A; Cuccurullo F; Patrono C; Patrignani P
    Clin Pharmacol Ther; 1995 Sep; 58(3):335-41. PubMed ID: 7554708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative irritancy of oxaprozin on the gastrointestinal tract of rats and mice: relationship to drug uptake and effects in vivo on eicosanoid metabolism.
    Rainsford KD
    Aliment Pharmacol Ther; 1988 Oct; 2(5):439-50. PubMed ID: 2979266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-inflammatory effects of etodolac: comparison with other non-steroidal anti-inflammatory drugs.
    Inoue K; Fujisawa H; Motonaga A; Inoue Y; Kyoi T; Ueda F; Kimura K
    Biol Pharm Bull; 1994 Dec; 17(12):1577-83. PubMed ID: 7735198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.